Effects of selective serotonin reuptake inhibitors on the placenta
Biology of Reproduction · 14.10.2025 · 113 (4) · 730-744
DOI: 10.1093/biolre/ioaf141 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biology of Reproduction, online erschienen am 28.06.2025. Verfasst von David T Ellenberger und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Sciences, University of Missouri, Columbia, Missouri, USA. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Placenta. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.
Abstract (Originalsprache)
The rate of depression in pregnant mothers has dramatically risen in the past few decades. One of the well-studied causes of depression is a deficiency of serotonin (5-HT) in the synaptic cleft of neurons in the central nervous system, called the serotonergic theory of depression. The serotonin transporter (SERT/SLC6A4) binds 5-HT such that it can no longer bind and activate its cognate receptors on the post-synaptic neurons. Greater number of pregnant women are prescribed a selective serotonin reuptake inhibitor (SSRI) drug to combat depression. These compounds act to bind to SERT, and thereby prolonging the duration 5-HT remains active within the synaptic cleft. While such treatments might be beneficial for the mother, the placenta and fetal brain can be inadvertently affected. SERT has been proposed to be the primary means by which the placenta internalizes maternal 5-HT and then transfers this neurotransmitter to the emerging brain, where it guides initial brain development. We consider evidence that SSRIs might influence the placenta-brain axis and contribute to gestational disorders, such as preeclampsia, fetal growth restriction, and gestational diabetes. Current data with rodent models, in vitro cell approaches with human trophoblast cell lines, and human epidemiological studies are reviewed. Gaps in our current understanding and future directions are discussed. A better understanding of how SSRIs might affect the placenta is crucial as by obstructing acquisition of maternal 5-HT by the placenta and downstream alterations on fetal brain development, these treatments might impact the lifelong health of sons and daughters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Sciences, University of Missouri, Columbia, Missouri, USA.
- Microbiology, University of Missouri, Columbia, Missouri, USA.
- Biological Sciences, University of Missouri, Columbia, Missouri, USA.
- Animal Sciences, University of Missouri, Columbia, Missouri, USA.
- MU Institute for Data Science and Informatics, University of Missouri, Columbia, Missouri, USA.
- Department of Genetics Area Program, University of Missouri, Columbia, Missouri, USA.
ORCID-Profile: Cheryl S Rosenfeld
Förderung
- NICHD NIH HHS
Zitieren
APA
Ellenberger, D. T., Herrington, R. T. B., Seda, S. E., Lambert, A. N., & Rosenfeld, C. S. (2025). Effects of selective serotonin reuptake inhibitors on the placenta. Biology of Reproduction, 113(4), 730-744. https://doi.org/10.1093/biolre/ioaf141
Vancouver
Ellenberger DT, Herrington RTB, Seda SE, Lambert AN, Rosenfeld CS. Effects of selective serotonin reuptake inhibitors on the placenta. Biology of Reproduction. 2025;113(4):730-744. doi:10.1093/biolre/ioaf141
BibTeX
@article{Ellenberger2025,
author = {Ellenberger, David T and Herrington, Rosalind T B and Seda, Sarah E and Lambert, Alyssa N and Rosenfeld, Cheryl S},
title = {Effects of selective serotonin reuptake inhibitors on the placenta},
journal = {Biology of Reproduction},
year = {2025},
volume = {113},
number = {4},
pages = {730--744},
doi = {10.1093/biolre/ioaf141}
}
EUVIMED